Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,240.0
5.5 (0.17%)

 

  • STI Straits Times Index
    3,240.0
    5.5 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,574.4
    -3.5 (-0.22%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    31.3 (0.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,827.2
    31.7 (0.13%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,244.1
    -5.1 (-0.08%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,246.1
    -21.1 (-0.93%)
    Index delayed 20 minutes
  • XAO XAO
    7,203.2
    4.2 (0.06%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 872.5M
  • Value: 729.0M
  • Rise: 113
  • Fall: 130
  • Unch: 575

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.104-0.001
ThaiBev0.795+0.005
Rex Intl0.181+0.007
Spackman0.018+0.002
Golden Agri-Res0.225-
Genting Sing0.910-0.005
Joyas Intl0.003-
OEL0.023-0.001
YZJ Shipbldg SGD1.040-0.020
AusGroup^0.042+0.003

World Indices

World Indices
Name Last Change
Nasdaq 9,314.9 -87.6
HSI 27,940.5 +31.3
HSCEI 10,969.3 +17.0
Jakarta 6,244.1 -5.1
Nikkei 225 23,827.2 +31.7
SSE Comp 2,976.5
Shanghai A 3,118.9
Shanghai B 248.6
PSE Comp 0.0
KOSPI 2,246.1 -21.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

DPHARMA DUOPHARMA BIOTECH BERHAD
Quotes 15 Minutes Delayed. Updated at 23 Jan 2020 16:57
Last (MYR): 1.670 Change: +0.020 High: 1.680 Remarks: s
Remarks legend:
RemarksDescriptionRemarksDescription
IOrder entry forbiddenAOrder entry authorized
GFrozenSSuspended
RReservedsShort selling available
[x]Exclude dividend[c] Cum dividend
Change (%): +1.21 Low: 1.650
Open 1.650 Yesterday's Close 1.650
Buy Price 1.670 Sell Price 1.680
Buy Volume ('00) 4 Sell Volume ('00) 150
Cumulative Volume ('00) 7,231 Cumulative Value 1,201,502
Click to show Stock Prices chart

Latest News

View All News

Key Statistics

EPS (MYR) a 0.06961 Trailing EPS (MYR) e 0.08418 NAV (MYR) b 0.7429
PE a 23.991 Trailing PE f 19.839 Price / NAV b 2.2479
Dividend (MYR) d 0.053192 Cash In Hand (MYR) g 0.1346 Issued & Paid-up Shares c 684,383,000
Dividend Yield (%) d 3.185 Price / Cash In Hand g 12.407 Treasury Shares h -
Beta - 75 Daysi 0.609 R-Squared - 75 Days(%)i 3.39 Market Cap (M) 1,142.920
Beta - 500 Daysi 0.863 R-Squared - 500 Days (%)i 7.83 Enterprise Value (M) 1,315.137
Piotroski F Score 6 Exchange Code 7148 Par Value ( MYR ) 0.50000
52 Weeks Volatility (%) 23.63 6-Month VWAP 1.444 Free Float (%) 42.0
Shariah Compliant Stocks Yes
Sector & Industry Health Technology - Biotechnology
Index Components BM HEALTH CARE
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 15 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 15 Nov 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference DPHARMA Bursa 1,142.920 23.991 19.839 2.2479 3.185
Industry Biotechnology Bursa 589.949 26.938 21.736 2.2511 3.085
PHARMACEUTICALS Bursa 521.239 17.023 17.405 1.7986 3.214
Index BM HEALTH CARE Bursa 6,041.090 49.364 42.260 2.9743 0.985
Local Peer MGRC Bursa 23.290 - - 1.4822 -
Global Peer AMGEN INC NASDAQ 134,041.969 15.969 16.616 12.2671 2.480
Global Peer CSL ASX 141,021.137 52.562 52.563 18.8452 0.854
Global Peer GILEAD SCIENCES INC NASDAQ 79,894.223 14.646 29.667 3.8776 3.659
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 58,902.779 28.097 27.476 11.2123 -
Global Peer BIOGEN INC NASDAQ 50,188.138 11.327 9.302 3.5859 -
Global Peer ILLUMINA INC NASDAQ 46,978.260 56.874 48.282 10.5831 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,910.353 15.509 17.680 3.6090 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,376.752 86.636 25.562 5.7660 0.692
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,295.304 300.197 15.844 2.2470 -
Other Global Peers SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), 3SBIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALLOGENE THERAPEUTICS INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), NATERA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), KODIAK SCIENCES INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), XENCOR INC (NASDAQ), VIELA BIO INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), INSMED INC (NASDAQ), ALECTOR INC (NASDAQ), REGENXBIO INC (NASDAQ), ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), LIGAND PHARMACEUTICAL INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), POLYNOVO LIMITED (ASX), COHERUS BIOSCIENCES INC (NASDAQ), NEXTCURE INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), FRONTAGE (HKEx), ENANTA PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), OPKO HEALTH INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), AVITA MEDICAL LTD (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), XBIOTECH INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), VIVA BIOTECH (HKEx), RADIUS HEALTH INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NYSE), ASCENTAGE-B (HKEx), CYTOKINETICS INC (NASDAQ), RETROPHIN INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), IMMUNOGEN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), AVROBIO INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), NANOVIRICIDES INC (NYSE American), MACROGENICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), SINOMAB BIO-B (HKEx), AGENUS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), MERUS B V (NASDAQ), BELLUS HEALTH INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), TRANSLATE BIO INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), RIGEL PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), ESSEX BIO-TECH (HKEx), COMPUGEN (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), IVERIC BIO INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), STEMLINE THERAPEUTICS INC (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), NEXT SCIENCE LTD (ASX), KAMADA (NASDAQ), GERON CORP (NASDAQ), TELIX PHARMACEUTIC (ASX), PFENEX INC (NYSE American), WAVE LIFE SCIENCES LTD (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NOVAVAX INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), BBI LIFE SCI (HKEx), VBI VACCINES INC CDA (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), AFFIMED N V (NASDAQ), SERES THERAPEUTICS (NASDAQ), IMV INC (NASDAQ), ATHERSYS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), XOMA CORP (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), GLYCOMIMETICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), CONTRAFECT CORP (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), X4 PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), CEL-SCI CORP (NYSE American), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), UNI-BIO GROUP (HKEx), TRILLIUM THERAPEUTICS INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), AVALON GLOBOCARE CORP (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), COHBAR INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), IMUGENE LIMITED (ASX), VACCINEX INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), SESEN BIO INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), TREVENA INC (NASDAQ), ORGENESIS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), EQUILLIUM INC (NASDAQ), INFLARX N V (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), SYNLOGIC INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VERMILLION INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), MICROBOT MEDICAL INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ORTHOCELL LIMITED (ASX), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), CT ENTERPRISE (HKEx), T2 BIOSYSTEMS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ADVAXIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ISORAY INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), ZAFGEN INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), ALIMERA SCIENCES INC (NASDAQ), BIOSINO BIO-TEC (HKEx), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), OCUGEN INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), BIOTRON (ASX), CO DIAGNOSTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), ANTEOTECH LIMITED (ASX), REGENT PACIFIC (HKEx), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), DARE BIOSCIENCE INC (NASDAQ), IBIO INC (NYSE American), ATYR PHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), VAXART INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ORAGENICS INC (NYSE American), CCP TECHNOLOGIES LTD (ASX), EXTRAWELL PHAR (HKEx), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), BIO-PATH HOLDINGS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED (ASX), PRECIPIO INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), CELLMID LIMITED (ASX), CLEVELAND BIOLABS INC (NASDAQ), PATRYS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), Suntar Eco-City^ (SGX), CONATUS PHARMACEUTICALS INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), TOCAGEN INC (NASDAQ), TROVAGENE INC (NASDAQ), REGENEUS LTD (ASX), BIOCEPT INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), OPGEN INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XENETIC BIOSCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), QT Vascular (SGX), LIVING CELL TECHNOLOGIES (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), NANOLLOSE LTD (ASX), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days -+0.060
+3.73 %
20 Days -+0.280
+20.14 %
Medium Term Return 3 Months -+0.310
+22.79 %
6 Months 0.010+0.270
+20.00 %
1 Year 0.050+0.705
+78.24 %
Long Term Return 2 Years 0.125+0.461
+48.47 %
3 Years 0.190+0.766
+105.75 %
5 Years 0.455+0.689
+116.62 %
Annualised Return Annualised --
+16.72 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.955 - 1.780 Change From 1 Year Low +0.715 % Change From 1 Year Low (%) +74.87
Change From 1 Year High -0.110 % Change From 1 Year High (%) -6.18
2 Years Range 0.925 - 1.780 Change From 2 Years Low +0.745 % Change From 2 Years Low (%) +80.54
Change From 2 Years High -0.110 % Change From 2 Years High (%) -6.18
5 Years Range 0.814 - 1.780 Change From 5 Years Low +0.856 % Change From 5 Years Low (%) +105.08
Change From 5 Years High -0.110 % Change From 5 Years High (%) -6.18
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

CCM Duopharma Biotech Berhad, an investment holding company, engages in the manufacture, distribution, import, and export of pharmaceutical products and medicines in Malaysia. It offers various over the counter products, including analgesic/anti-pyretics, antibacterial mouthwash, childrens vitamins, cough preparations, dermatology products, eye drops, first aid dressings, and health suppliments. The company provides its products in various forms, such as tablets, capsules, syrup, oral antibiotic, creams, haemodialysis solution, sterile irrigation solution, sterile powder injectables, small volume injectables, dental cartridges, and eye drop preparations. It exports its products to various countries, including Vietnam, Ethiopia, Sudan, South East Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, Republic of Yemen, Singapore, and Hong Kong. The company was founded in 1979 and is based in Klang, Malaysia. CCM Duopharma Biotech Berhad is a subsidiary of CCM Marketing Sdn. Bhd.

IPO Performance

Listing Date 18 Jul 2002 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) 7.50 Public Offer Subscription Rate (x) -
IPO Price (MYR) 2.100 First Day Close (MYR) 1.043 First Week Close (MYR) 1.006
Current vs IPO Price (%) -20.48 First Day Gain (%) -50.33 First Week Gain (%) -52.10

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(2.61 MB)
Part 2(2.17 MB)
Annual Report 2018 Apr 2018 Part 1(1.46 MB)
Part 2(0.88 MB)
Part 3(0.27 MB)
Part 4(2.43 MB)
Part 5(1.63 MB)
Annual Report 2016 Dec 2016 Part 1(2.85 MB)
Part 2(0.73 MB)
Annual Report 2015 Dec 2015 Part 1(0.08 MB)
Part 2(2.44 MB)
Part 3(0.02 MB)
Part 4(0.04 MB)
Annual Report 2014 Dec 2014 Part 1(2.20 MB)
Annual Report 2013 Dec 2013 Part 1(1.34 MB)
Annual Report 2012 Dec 2012 Part 1(1.64 MB)
Annual Report 2011 Dec 2011 Part 1(1.12 MB)
Part 2(0.11 MB)
Annual Report 2010 Dec 2010 Part 1(2.37 MB)
Annual Report 2009 Dec 2009 Part 1(2.87 MB)
Part 2(0.15 MB)
Annual Report 2008 Dec 2008 Part 1(0.82 MB)
Annual Report 2007 Dec 2007 Part 1(0.04 MB)
Part 2(2.16 MB)
Annual Report 2006 Dec 2006 Part 1(1.01 MB)
Part 2(0.02 MB)
Annual Report 2005 Dec 2005 Part 1(0.30 MB)
Part 2(0.82 MB)
Annual Report 2004 Dec 2004 Part 1(0.52 MB)
Part 2(1.35 MB)
Annual Report 2003 Dec 2003 Part 1(0.63 MB)
Annual Report 2002 Dec 2002 Part 1(1.12 MB)
Part 2(0.42 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
24 Jan 2020 1.680 1.690 1.670 1.690 1,219,900 1.6755
23 Jan 2020 1.650 1.680 1.650 1.670 723,100 1.6616
22 Jan 2020 1.700 1.720 1.640 1.650 4,480,800 1.6724
21 Jan 2020 1.610 1.690 1.610 1.680 1,365,700 1.6621
20 Jan 2020 1.620 1.630 1.580 1.600 1,162,100 1.5941
17 Jan 2020 1.680 1.680 1.620 1.630 407,000 1.6351
16 Jan 2020 1.660 1.680 1.650 1.670 905,100 1.6614
15 Jan 2020 1.700 1.780 1.660 1.670 4,365,300 1.6903
14 Jan 2020 1.620 1.700 1.620 1.690 1,245,400 1.6695
13 Jan 2020 1.610 1.630 1.600 1.620 728,300 1.6181
10 Jan 2020 1.610 1.630 1.590 1.610 1,825,700 1.6078
09 Jan 2020 1.560 1.620 1.560 1.610 1,874,700 1.5990
08 Jan 2020 1.560 1.570 1.510 1.540 1,531,000 1.5408
07 Jan 2020 1.480 1.580 1.460 1.580 548,500 1.5192
06 Jan 2020 1.480 1.490 1.470 1.470 250,700 1.4760
03 Jan 2020 1.460 1.500 1.460 1.480 920,500 1.4823
02 Jan 2020 1.410 1.480 1.410 1.460 570,800 1.4513
31 Dec 2019 1.390 1.430 1.390 1.420 311,200 1.4203
30 Dec 2019 1.410 1.420 1.390 1.400 181,700 1.4038
27 Dec 2019 1.390 1.410 1.390 1.400 477,800 1.3967
26 Dec 2019 1.400 1.410 1.390 1.390 256,100 1.3929
24 Dec 2019 1.400 1.420 1.400 1.410 28,000 1.4130
Summary
Current 2 Weeks
(13 Jan 2020 to 24 Jan 2020)
1.610 1.780 1.580 1.690 16,602,700 -
Previous 2 Weeks
(27 Dec 2019 to 10 Jan 2020)
1.390 1.780 1.390 1.610 8,492,600 -
4 Weeks from
(28 Nov 2019 to 26 Dec 2019)
1.410 1.780 1.380 1.390 9,887,100 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.